alexa New Highlights in the Treatment of Progressive Multiple Sclerosis | OMICS International| Abstract
ISSN: 2376-0389

Journal of Multiple Sclerosis
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Mult Scler (Foster City) 2019, Vol 5(2): 223
  • DOI: 10.4172/2376-0389.1000223

New Highlights in the Treatment of Progressive Multiple Sclerosis

Sapko K*, Jamroz-Wisniewska A, Kulczynski M, Marciniec M, Szczepanska-Szerej A and Rejdak K
Department of Neurology, Medical University of Lublin, Poland
*Corresponding Author : Sapko K, Department of Neurology, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland, Tel: +48 607 455 195, Email: [email protected]

Received Date: Jan 02, 2019 / Accepted Date: Jan 18, 2019 / Published Date: Jan 24, 2019

Abstract

Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system. Most patients have a relapsing-remitting disease type, for which medicines are mostly dedicated. Clinical course of some patients will transition to secondary progressive multiple sclerosis and small portion of patients is classified as primary progressive multiple sclerosis from the beginning. The treatment of progressive multiple sclerosis has been limited for a long time, however, for a few years attention has been paid to the need for new disease modifying drugs that would focus on the treatment of progressive multiple sclerosis. The breakthrough was ocrelizumab, which is the first medicine registered in the treatment of primary progressive multiple sclerosis, while siponimod is planned to be approved soon in the treatment of secondary progressive multiple sclerosis. Numerous studies are currently underway on new substances with anti-inflammatory, neuroprotective or remyelinating effects such as high-dose biotin, ibudilast, simvastatin, alpha lipoic acid or clemastine. The first research results are very promising nevertheless, more accurate drug research is needed.

Keywords: Multiple sclerosis; Progressive multiple sclerosis; Treatment; Clinical trials.

Citation: Sapko K, Jamroz-Wisniewska A, Kulczynski M, Marciniec M, Szczepanska-Szerej A, et al. (2019) New Highlights in the Treatment of Progressive Multiple Sclerosis. J Mult Scler (Foster City) 5: 223. Doi: 10.4172/2376-0389.1000223

Copyright: © 2019 Sapko K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Article Usage
  • Total views: 3515
  • [From(publication date): 0-0 - Dec 14, 2019]
  • Breakdown by view type
  • HTML page views: 3344
  • PDF downloads: 171
Top